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Background: Oxaliplatin, an effective antineoplastic agent againstgastrointestinal tumors, can cause severe
peripheral neurotoxicity, which seriously limits its clinical application. To date, there are no effective treatments for
this complication. Ganglioside-monosialic acid (GM1) has been shown to protect neurons against injuries and
degeneration. The aim of this study was to evaluate the effects of GM1 on preventing oxaliplatin-induced
neurotoxicity in patients with gastrointestinal tumors.
Methods: In this study, 120 patients with gastrointestinal tumors were enrolled, andthey received the treatment of
XELOX (oxaliplatin and capecitabine) and FOLFOX4 (oxaliplatin, leukovolin and 5-fluorouracil). The patients were
randomly divided into two groups, the experimental group and control group, with60 patients ineach. On the day
chemotherapy was initiated, the experimental group received GM1 intravenously (100 mg once daily) for 3 days,
while no neuroprotective agents were applied in the control group. The incidence rates and classification of
neurotoxicity in the two groups were evaluated and the differences between the two groups were examined.
Furthermore, whether GM1 affected the therapeutic effects of chemotherapy was also examined.
Results: The grade of neurotoxicity in the experimental group was significantly lower than in the control group
(P<0.05, Mann–Whitney U test). The probability of occurrence of low-grade neurotoxicity (grade 0 and 1) in the
experimental group was higher than that in the control group (logistic ordinal regression); whereas the probability
of occurrence of high-grade neurotoxicity (grade 2 and 3) in the experimental group was lower than in the control
group (logistic ordinal regression).
Conclusion: The data suggested that GM1 could reduce the grade of oxaliplatin-induced neurotoxicity and was an
effective neuroprotective agent against oxaliplatin-induced high-grade neurotoxicity in patients with gastrointestinal
tumors.
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Oxaliplatin is one of the major antineoplastic agents in
the treatment of gastrointestinal tumors [1]. Its major
toxic side effect is peripheral neurotoxicity, which mainly
causes sensory disturbances in the lower extremities [2].
Oxaliplatin-induced neurotoxicity has been classified into
two types: acute and chronic neurotoxicity. The mechan-
ism underlying oxaliplatin-induced acute neurotoxicity is* Correspondence: jiaosc2009@126.com
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reproduction in any medium, provided the orthat oxaliplatin affects the voltage-gated sodium channels
in the surface of the cell membrane of nerve fibers [3]. In
five clinical trials involving 210 patients, reversible signs
and symptoms of acute neuropathy were found to occur
in 82 to 98% of treated patients [4]. The mechanism
underlying oxaliplatin-induced chronic neurotoxicity is
that oxaliplatin inhibits the synthesis of rRNA in the nu-
cleolus of neuronal cell bodies, resulting in morphological
change and damage of sensory neurons [5]. Grothey and
Cersosimo reportedthat the incidence of chronic neuro-
toxicity (grade 3/4) was about 16% [6,7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mainly prevented by regulating sodium channels inclinic.
The approaches to regulate sodium channels include so-
dium channel blockers, and calcium and magnesium
infusions. However, itremains controversial whether cal-
cium and magnesium infusions can reduce the efficiency
of oxaliplatin [8,9]. It is reported that glutathione can
prevent accumulation of platinum agents in the dorsal
root ganglion (DRG), and thus glutathione can be used
to prevent and treat oxaliplatin-induced chronic neuro-
toxicity [10]. Furthermore, amifostine can also prevent
neurotoxicity induced by chemotherapy drugs such as
paclitaxel and cisplatin [11]. However, these drugs ex-
hibit limited efficacy in the prevention and treatment of
oxaliplatin-induced neurotoxicity. Therefore, there is an
urgent need to develop new drugs to prevent and treat
oxaliplatin-induced neurotoxicity [12].
Ganglioside-monosialic acid (GM1) is a type of glyco-
sphingolipid with one sialic acid. GM1 is located on the
outer layer of the plasma membrane, and plays a vital
role in neurogenesis, nerve development, differentiation
and repair after injury [13]. Currently, preclinical re-
search has demonstrated the potential neuroprotective
effects of GM1 in central nervous system diseases and
Parkinson’s disease [14-16]. Notably, GM1 is also used
in the treatment of peripheral neuropathy such as dia-
betic peripheral neuropathy in preclinical animal models,
owing to its superior neuroprotective effects and func-
tion of nerve repair [17].
The mechanisms whereby GM1 exert their superior
neuroprotective effects and function of nerve repair in-
clude: 1. GM1 can recover the activity of Na+-K+-ATP
enzyme and Ca2+-Mg2+-ATP enzyme, and promote the
regeneration and recovery of nerves [18]. 2. GM1 can
interact with nerve growth factor (NGF) to promote the
regeneration of nerves [19]. 3. GM1 can inhibit the lipid
peroxidation and remove oxygen free radicals, reducing
the damage of nerve cells [20]. 4. GM1 can affect the
morphological changes of DRG neurons and protect the
DRG neurons from damage induced by excitotoxic glu-
tamate [21]. Considering DRG neurons are a target for
neurotoxicity induced by oxaliplatin, GM1 may exert its
neuroprotective effects by affecting DRG neurons. In re-
cent years, GM1 has been used in the prevention of
neurotoxicity induced by chemotherapy drugs such as
paclitaxel in preclinical animal models [22]. However,
there are no reports of the effects of GM1 in the preven-
tion of oxaliplatin-induced peripheral neurotoxicity.
In this study, 120 patients with gastrointestinal tumors
were enrolled and received the treatment of XELOX and
FOLFOX4. The patientswere randomly divided into two
groups, the experimental group and control group,with
60 patients in each. The incidence rates and classifica-
tion of neurotoxicity in the two groups were evaluated.The aim of this study was to evaluate the effects of GM1




In this study, 120 patients were enrolled with gastrointes-
tinal tumors (gastric cancer or colorectal cancer). They
received chemotherapy containing oxaliplatin at the
Department of Medical Oncology, Chinese PLA General
Hospital, during a 1-year period from December 2010
to December 2011. All the patients had an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0 to 1. Forty-nine patients (40.8%) underwent adjuvant
chemotherapy after surgery for gastric cancer. Seven
patients (5.8%) underwent first-line chemotherapy for gas-
tric cancer. Twenty-two patients (18.3%) underwent adju-
vant chemotherapy after surgery for rectal cancer. Eleven
patients (9.2%) underwent first-line chemotherapy for rec-
tal cancer. Eighteen patients (15%) underwent adjuvant
chemotherapy after surgery for colon cancer. Thirteen
patients (10.8%) underwent first-line chemotherapy for
colon cancer.
The patients were randomly divided into two groups, the
experimental group and control group, with 60 patients in
each. The assignation to the two groups was generated by
using a computer program, Randomlogue, produced by the
Department of Social Statistics, Southampton University,
UK. Only the fourth author, TFJ, who applied the treat-
ment, was aware of the group assignment of each patient,
and TFJ did not participate in any of the subsequent evalu-
ation phases. The first author, YYZ, and second author, JLY,
undertook the evaluation, and YYZ and JLY were blinded
to the group assignment of each patient.
The further criteria for inclusion in this study were:
aged between 18 to 75 years and life expectancy >3
months; ECOG performance status of 0 to 1; tumors
demonstrated as gastric cancer or colorectal cancer by
pathology, and treated by chemotherapy containing oxa-
liplatin; routine blood tests performed 0 to 3 days before
chemotherapy (absolute neutrophil ≥1.5 × 109/L, plate-
lets ≥100 × 109/L and hemoglobin ≥9 g/dL); hepatic
function test (aspartate aminotransaminase and alanine
aminotransferase lower than 1.5 fold of the upper limit
of normal values, and lower than 2.5 fold of the upper
limit of normal values in patients with known hepatic
metastases); renal function test (a calculated creatinine
clearance rate <45 mL/min); and without any neurotox-
icity (grade 0).
Patients with signs of malnourishment or >10% weight
loss in the previous 6 weeks, or other serious concomi-
tant disorders were excluded from the therapy. Patients
were discontinued from the therapy in the case of
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despite dose adjustment.
This study was conducted according to the International
Conference on Harmonisation (ICH) Good Clinical
Practice (GCP) guidelines, including obtaining written
informed consent from all patients. This study was regis-
tered at the Department of Scientific Research, Chinese
PLA General Hospital (register number: 2007–3048).
Sample size
The sample size was calculated based on significant
neurotoxicity relief. Considering a 0.05 two-sided signifi-
cance level, a power of 80% and an allocation ratio of 1:1,
55 patients were required in each group [23]. Allowing for
a 10% attrition/non-compliance rate, 60 subjects were
required.
Medication
All 120 patients underwent oxaliplatin-containing chemo-
therapy consisting of XELOX (oxaliplatin 130mg/m2
Vdday 1; capecitabine 850 to 1000 mg/m2twice dailyday 1
to 14; repeat day 21) and FOLFOX4 (oxaliplatin 85mg/m2
Vd day 1; leukovolin 200mg/m2 Vdday 1 to 2; 5-
fluorouracil 400 mg/m2intravenouslyday 1 to 2, 600 mg/
m2by continuous intravenous infusionfor 22 hours day 1
to 2; repeat day 14). On the day chemotherapy was
initiated, the experimental group received GM1 (Qilu
Pharmaceutical Co., Ltd, Shandong, China) intravenously
(100 mg once daily, according to the manufacture’s proto-
cols), before chemotherapeutics administration for 3 days;
while no neuroprotective agents were applied in the con-
trol group.
Objectives
This study seeks to evaluate whether GM1 is an effect-
ive neuroprotective agent against oxaliplatin-induced
high-grade neurotoxicity in patients with gastrointes-
tinal tumors.
Neurotoxicity grading scales
Fourteen (for the 2-week regimen) or twenty-one (for
the 3-week regimen) days after each chemotherapeutic
cycle, the incidence rates and classification of neurotox-
icity in the two groups were comprehensively evaluated
using the National Cancer Institute (NCI)-Sanofi criteria
(Table 1) [24]. The neurotoxicity was recorded after eachTable 1 Neurotoxicity grading scales
Standard
setting unit
Grade 1 Grade 2
NCI-Sanofi
criteria
Paresthesias or dysesthesias of
short duration that resolve and
do not interfere with function
Paresthesias or dysesthesia
interfering with function b
not activities of daily living
NCI, National Cancer Institute.chemotherapeutic cycle and the most severe neurotox-
icity in all chemotherapeutic cycles was recorded as the
final recorded neurotoxicity of each patient.
Response Evaluation Criteria In Solid Tumors (RECIST)
The enrolled patients were classified into two categories:
adjuvant chemotherapy after surgery and first-line chemo-
therapy. The clinical evaluation of the patients undergoing
first-line chemotherapy, who all had measurable target
lesions, was performed according to the RECIST pro-
posed by Therasse et al. [25], which described: Complete
Response (CR): disappearance of all target lesions; Partial
Response (PR): at least a 30% decrease in the sum of the
longest diameter (LD) of target lesions, taking as reference
the baseline sum LD; Stable Disease (SD): neither sufficient
shrinkage to qualify for PR nor sufficient increase to qualify
for PD, taking as reference the smallest sum LD since the
treatment started; Progressive Disease (PD): at least a 20%
increase in the sum of the LD of target lesions, taking as
reference the smallest sum LD recorded since the treat-
ment started or the appearance of one or more new lesions.
Statistical analysis
All data in this study were processed using SPSS 13.0
software (IBM, Armonk, NY, USA). For group compari-
sons, unordered categorical variables were compared
using chi-square (χ2) test or Fisher’s exact test, measure-
ment data were compared using Student’s t-test, and or-
dinal variables of multi-classification were compared
using Mann–Whitney U test. Logistic ordinal regression
was used to determine correlations in classification of
neurotoxicity between the experimental group and con-
trol group. A P value <0.05 was considered statistically
significant.
Results
The general and clinicopathological characteristics of
the 120 patients are shown in Table 2. There were no
significant differences in gender, diagnosis, therapeutic
approaches, smoking or drinking status, complicated
diseases and chemotherapy regimens between the two
groups (Table 2). The age of patients ranged from 21 to
74 years, with an average age of 54.96 years. In the experi-
mental group, the fewest and most chemotherapeutic
cycles were 2 and 12, respectively, with an average cycle
of 5.88. The cumulative oxaliplatin dose (130 mg/m2Grade 3 Grade 4
s
ut
Paresthesias or dysesthesias with pain
or functional impairment that also




Table 2 General and clinicopathological characteristics of patients (n = 120)
Groups Experimental group Control group P value
Frequency Percentage (%) Frequency Percentage (%)
Gender Male 49 81.67 44 73.33 0.274a
Female 11 18.33 16 26.67
Diagnosis Colon cancer metastases 6 10 6 10 0.066a
Postoperative colon cancer 8 13.33 11 18.33
Gastric cancer metastases 4 6.67 3 5
Postoperative gastric cancer 32 53.33 17 28.33
Rectal cancer metastases 3 5 7 11.67
Postoperative rectal cancer 7 11.67 16 26.67
First-line therapy No 44 73.33 43 71.67 0.838a
Yes 16 26.67 17 28.33
Smoking No 38 63.33 39 65.00 0.849a
Yes 22 36.67 21 35.00
Drinking No 46 76.67 40 66.67 0.224a
Yes 14 23.33 20 33.33
Diabetes No 51 85.00 54 90.00 0.408a
Yes 9 15.00 6 10.00
Chemotherapy regimen FOLFOX4 13 21.67 20 33.33 0.152a
XELOX 47 78.33 40 66.67
Clinical evaluation CR 1 1.67 1 1.67 ndb
PD 2 3.33 3 5.00
PR 7 11.67 3 5.00
SD 6 10.00 10 16.67
Assistance 44 73.33 43 71.67
aComparisons performed using χ2 test; bThe sample number is small and comparisons are not done. CR, Complete Response;nd, not done; PD,Progressive Disease;
PR, Partial Response;SD,Stable Disease.
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cycles) of the experimental group ranged from 227.27 to
1103.90 mg/m2. In the control group, the fewest and most
chemotherapeutic cycles were 3 and 12, respectively, with
an average cycle of 6.63. The cumulative oxaliplatin dose
of the control group ranged from 384.62 to 1077.84 mg/
m2. There was no significant difference in average cumu-
lative oxaliplatin dose between the experimental group
and control group (692.08 ± 196.08 mg/m2vs. 740.83 ±
222.65 mg/m2, mean ± SD, n = 60, P = 0.206, Student’s
t-test). There were no significant differences in age and
chemotherapeutic cycles between the two groups (Table 3).Table 3 Comparison of age and chemotherapeutic cycles










aComparisonsperformed using Student’s t-test.Neurotoxicity evaluation
After chemotherapy, the incidence rates and classification
of neurotoxicity in the two groups were comprehensively
evaluated using the neurotoxicity grading scales, and the
differences between the two groups were examined. All
patients exhibited grade 0 to 3 neurotoxicity, and no
patients exhibited grade 4 neurotoxicity. In our study, the
incidence of neurotoxicity (grade 1, 2 and 3) in the experi-
mental group was 68.33%; while that in the control group
was 78.33%. The incidence rates of grade 0 neurotoxicity
in the experimental and control group were 31.67% and
21.67%, respectively. Grade 1 was 33.33% and 26.67%, re-
spectively. Grade 2 was 26.67% and 23.33%, respectively.
Grade 3 was 8.33% and 26.33%, respectively. The grade of
neurotoxicity in the experimental group was significantly
lower than in the control group (P = 0.021, Mann–Whitney
U test) (Table 4). Notably, the probability of occurrence of
high-grade (grade 2 and 3) neurotoxicity in the experimen-
tal group was lower than that in the control group (grade 2:
21.64% vs. 29%, grade 3: 12.95% vs. 24.32%, logistic ordinal
regression). Owing to the lower probability of occurrence
Table 4 Comparison of the grade of neurotoxicity between the two groups
Grade of
neurotoxicity
Experimental group Control group P valuea
Frequency Percentage (%) Frequency Percentage (%)
0 19 31.67 13 21.67 0.021
1 20 33.33 16 26.67
2 16 26.67 14 23.33
3 5 8.33 17 28.33
aComparisons performed using Mann–Whitney U test.
Zhu et al. World Journal of Surgical Oncology 2013, 11:19 Page 5 of 7
http://www.wjso.com/content/11/1/19of high-grade (grade 2 and 3) neurotoxicity in the experi-
mental group than the control group, the probability of oc-
currence of low-grade (grade 0 and 1) neurotoxicity in the
experimental group was higher than that in the control
group (grade 0: 33.77% vs. 19.09, grade 1: 31.64% vs.
27.58%, logistic ordinal regression) (Tables 5 and 6). There
were significant differences in the probability of occurrence
of neurotoxicity between the two groups (P = 0.041, χ2 test)
and the probability of occurrence of grade 3 neurotoxicity
was significantly lower in the experimental group than in
the control group (P = 0.005, χ2 test).
In the experimental group, six patients exhibited grade
2 to 3 neurotoxicity 1 to 3 months after chemotherapy;
but only one patient exhibited such neurotoxicity in the
control group. During the treatment, four cases of severe
allergy occurred, with three in the experimental group
and one in the control group. The severe allergy all oc-
curred during the administration of oxaliplatin and after
its repeated administration, with associated symptoms of
breathing difficulties, sweating, pale and cyanotic lips,
which were relieved within 20 minutesfollowing oxygen
and anti-allergy treatment. Two patients underwent sur-
gical treatment after chemotherapy and exhibited severe
neurotoxic symptoms after surgery. One patient exhib-
ited torpid reaction and memory loss. Twenty-five per-
cent of patients exhibited decreased visual acuity and/or
hypogeusia. There was no significant difference in the
incidence rates of decreased visual acuity and/or hypo-






[Grade = 0.00] −1.444 0.281
Dependent variable [Grade =1.00] −0.133 0.246
[Grade = 2.00] 1.135 0.274
Independent variable [Class = 1.00] −0.770 0.334
[Class = 2.00] 0.000
aThe logistic model was successfully constructed, demonstrated by χ2= 5.402 and P
neurotoxicity in the experimental group was 2.16, suggesting the probability of occ
was significantly higher than that in the control group.duration of remission of decreased visual acuity and/or
hypogeusia was still in follow-up.
Discussion
Oxaliplatin-induced neurotoxicity is a common, poten-
tially severe and dose-limiting adverse effect of cancer
treatment [26]. The characteristics of oxaliplatin-induced
neurotoxicity are related to dose intensity and cumulative
dose. Neurotoxicity can profoundly affect the qualityoflife,
often compelling clinicians to lower the chemotherapy
regimen, consequently limiting therapeutic efficacy [27].
Oxaliplatin-induced neuropathy is of two types: acute and
chronic. Acute neuropathy was believed to reflect a state of
peripheral nerve hyperexcitability that likely represents a
transient oxaliplatin-induced impairment of ion channels,
while the chronic treatment induces an axonal neuropathy
similar to the other platinum-based drugs [28]. Strategies to
ameliorate oxaliplatin neurotoxicity include the use of sev-
eral ‘neuroprotective’ drugs, such as reduced glutathione
[29], amifostine [30], andcalcium and magnesium infusion.
[31]. GM1 is used in the treatment of peripheral neur-
opathy such as diabetic peripheral neuropathy in preclinical
animal models, owingto its superior neuroprotective effects
and function of nerve repair. To our knowledge, the clinical
use of GM1 in the prevention of oxaliplatin-induced neuro-
toxicity has not yet been investigated.
Four of the enrolled patients (3.33%) presented with
dyspnea, which was a little higher than that of a previous
study (1 to 2%) [32]. The dyspnea of these four patientsin the grade of neurotoxicity using logistic ordinal
Wald Degree of
freedom
P value 95% confidence interval
Lower limit Upper limit
26.388 1 0.000 −1.995 −0.893
0.292 1 0.589 −0.616 0.350
17.124 1 0.000 0.598 1.673
5.317 1 0.021 −1.425 −0.116
= 0.020. The regression coefficient was −0.770, thus the odds ratio of
urrence of low-grade neurotoxicity (grade 0 and 1) in the experimental group
Table 6 Predicative probability of neurotoxicity in the
two groupsa
Groups Grade of neurotoxicity
0 1 2 3
Observed value 19 20 16 5
Experimental group Predicative value 20.26 18.98 12.98 7.77
Predicative probability 33.77 31.64 21.64 12.95
Observed value 13 16 14 17
Control group Predicative value 11.46 16.55 17.40 14.59
Predicative probability 19.09 27.58 29.00 24.32
aThe probability of low-grade (grade 0 and 1) neurotoxicity occurring in the
experimental group was higher than in the control group, while the
probability of high-grade (grade 2 and 3) neurotoxicity occurring in the
experimental group was lower than in the control group.
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went complete chemotherapy after intravenous drip was
slowed. Only one patient developed dyspnea again when
undergoing chemotherapy and the other three patients
did not develop symptoms of dyspnea again. It is reported
that multi-infusion and prolongation of the infusion time
could reduce the neurotoxicity of oxaliplatin [33,34]. The
dyspnea that occurred in the patients may be associated
with the rapid infusion of oxaliplatin. Whether GM1 has
causative or therapeutic effects on dyspnea is not clearand
the effects of GM1 on dyspnea induced by oxaliplatin
should be observed in a clinical trial of a sufficiently larger
sample size.
Two patients who underwent surgery after chemotherapy
presented with postoperative aggravation of neurotoxicity,
which was consistent with previous reports that surgery
could aggravate neurotoxicity induced by oxaliplatin [35].
In the control group, one patient receiving the cumulative
dose of oxaliplatin of 1800 mg (1065.09mg/m2) presented
with torpid reaction, loss of memory and grade 3 neurotox-
icity. The results obtained by Lehky showed that rare
neurotoxicity such as urine retention, Lhermitte’s sign and
reversible posterior leukoencephalopathy syndrome could
occur when the cumulative dose of oxaliplatin exceeded
1000mg per patient [28]. Twenty-five percent of patients
exhibited decreased visual acuity and/or hypogeusia. There
was no significant difference in the incidence rates ofTable 7 Comparison of the incidence rates of decreased
visual acuity and/or hypogeusia between the two groups
Symptoms Experimental group Control group Sum P valuea
Yes Frequency 44 46 90 0.673
Percentage (%) 73.33 76.67 75.00
No Frequency 16 14 30
Percentage (%) 26.67 23.33 25.00
Sum Frequency 60 60 120
Percentage (%) 100.00 100.00 100.00
aComparisons performed using χ2 test.decreased visual acuity and/or hypogeusia between the two
groups, suggesting that GM1 could not prevent the toxic
effects of oxaliplatin on vision and taste receptors.
In our study, the total incidence of neurotoxicity in the
experimental group was 68.33%, while that in the control
group was 78.33%. However, the grade of neurotoxicity in
the experimental group was significantly lower than in the
control group (P = 0.021). Notably, the probability of oc-
currence of high-grade (grade 2 and 3) neurotoxicity in
the experimental group was lower than in the control
group (Table 6). There were significant differences in the
probability of occurrence of neurotoxicity between the
two groups (P = 0.041, χ2 test) and the probability of
occurrence of grade 3 neurotoxicity was significantly
lower in the experimental group than in the control group
(P = 0.005, χ2 test). In the experimental group, six patients
did not present with neurotoxicity during treatment.
However, they presented with grade 2 or 3 neurotoxicity 1
to 3 months after chemotherapy. We speculated that this
phenomenon was due to the short-term application of
GM1. Owing to limited length of stay, the usage time of
GM1 per patient was only 3 days in this study, leading
to only partially preventive effects of GM1 exerted on
patients.
In this study, the drugs which were used to prevent
oxaliplatin-induced neurotoxicity mostly exhibited limited
efficacy. Notably, calcium and magnesium infusion was
reported to effectively decrease the incidence of chronic,
cumulative, grade 2 or greater oxaliplatin-induced neuro-
toxicity in a non-randomized and retrospective study
(P = 0.038). However, no effect on acute, cold-induced
neurotoxicity was found. No substantial differences in ad-
verse effects were noted between calcium/magnesium and
placebo. Comparing the results from these trials may be
difficult or impossible because of the use of different
dosages and regimens of treatment, and the lack of
standardization of the methods used in evaluating the ex-
tent or the incidence of neurotoxicity.Conclusion
In summary, these data suggest that GM1 could reduce
the grade of oxaliplatin-induced neurotoxicity and was an
effective neuroprotective agent against oxaliplatin-induced
high-grade neurotoxicity in patients with gastrointestinal
tumors. This study points to the potential of GM1 in re-
ducing the oxaliplatin-induced high-grade neurotoxicity in
patients with gastrointestinal tumors.Abbreviations
CR: Complete Response; DRG: Dorsal root ganglion; ECOG: Eastern
Cooperative Oncology Group; GM1: Ganglioside-monosialic acid; LD:
Longest diameter; NCI: National Cancer Institute; NGF: Nerve growth factor;
PD: Progressive Disease; PR: Partial Response; SD: Stable Disease; Vd: Volume
of distribution.
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